REGN - Regeneron Pharmaceuticals, Inc Stock Analysis
Regeneron Pharmaceuticals, Inc (REGN) is a publicly traded company listed on the NASD. It operates in the Biotechnology industry, part of the broader Healthcare sector. The company has a market capitalization of 80.32B, generates annual revenue of 14.34B, and reports net income of 4.50B. As of the latest data, the stock is trading at 759.86 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. The dividend yield (0.35%) is modest, often associated with growth-oriented companies. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.06), indicating current market sentiment. Institutional ownership is reported at 85.72%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 8.79%, trading within a 52-week range of 476.49 - 821.11.
REGN - Regeneron Pharmaceuticals, Inc
759.86
Analyst Consensus
Buy 4.06
REGN – Analyst Rating Summary
- Strong Buy: 11
- Buy: 16
- Hold: 9
- Sell: 0
- Strong Sell: 0
- Total Analysts: 36
| Index: | NDX, S&P 500 | P/E: | 18.28 | EPS (ttm): | 41.56 | Insider Own: | 3.74% | Shs Outstand: | 103.90M | Perf Week: | -2.79% |
| Market Cap: | 80.32B | Forward P/E: | 14.37 | EPS next Y: | 52.89 | Insider Trans: | -0.33% | Shs Float: | 101.75M | Perf Month: | -1.96% |
| Income(ttm): | 4.50B | PEG: | 1.31 | EPS next Q: | 9.13 | Inst Own: | 85.72% | Short Float: | 2.02% | Perf Quarter: | 5.00% |
| Revenue(ttm): | 14.34B | P/S: | 5.60 | EPS this Y: | 2.55% | Inst Trans: | 0.97% | Short Ratio: | 2.48 | Perf Half Y: | 33.96% |
| Book/sh: | 295.71 | P/B: | 2.57 | EPS next Y: | 16.40% | ROA: | 11.49% | Short Interest: | 2.05M | Perf Year: | 8.79% |
| Cash/sh: | 81.46 | P/C: | 9.33 | EPS next 5Y: | 10.99% | ROE: | 14.87% | 52W Range: | 476.49 - 821.11 | Perf YTD: | -1.56% |
| Dividend Est.: | 2.65 (0.35%) | P/FCF: | 19.68 | EPS past 3/5Y: | 2.76% 6.33% | ROIC: | 13.18% | 52W High: | 821.11 -7.46% | Beta: | 0.40 |
| Dividend TTM: | 3.58 (0.47%) | Quick Ratio: | 3.39 | Sales past 3/5Y: | 5.62% 11.04% | Gross Margin: | 81.56% | 52W Low: | 476.49 59.47% | Perf 5Y: | 64.63% |
| Dividend Ex-Date: | Feb 20, 2026 | Current Ratio: | 4.13 | EPS Y/Y TTM: | 5.49% | Oper. Margin: | 25.81% | RSI (14): | 45.80 | Volatility: | 3.12% 2.97% |
| Employees: | 15410 | Debt/Eq: | 0.10 | Sales Y/Y TTM: | 0.99% | Profit Margin: | 31.41% | Recom: | 1.70 | Target Price: | 880.36 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.09 | EPS Q/Q: | -2.57% | Payout: | 8.49% | Rel Volume: | 0.68 | Prev Close: | 764.93 |
| Sales Surprise: | 1.93% | EPS Surprise: | 6.56% | Sales Q/Q: | 2.51% | Earnings: | Jan 30 BMO | Avg Volume: | 828.21K | Price: | 759.86 |
| SMA20: | -2.58% | SMA50: | -1.54% | SMA200: | 18.29% | Undervalued: 15.86% | Volume: | 561,778 | Change: | -0.66% | |
Graham Classic formula value: 1137.49
(P/E=8 * 1g) Min value: 708.69
(current P/E * 2g) Max value: 1502.47
Average value: 1116.22
About Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.